Rapid Diagnostic Testing Analyzed in Suspected Meningitis Diagnosis
By LabMedica International staff writers Posted on 07 Dec 2021 |

Image: The FilmArray System Syndromic infectious disease testing impacts duration of empiric antibiotic therapy in suspected bacterial meningitis (Photo courtesy of BioFire Diagnostics)
Bacterial meningitis is a potentially fatal infection of the central nervous system (CNS) that is associated with significant complications including neurologic deficits and epilepsy in the majority of survivors.
Rapid diagnosis and treatment are critical to reducing morbidity and mortality; however, evaluation of suspected meningitis is complex and challenging due to its nonspecific presentation, the limited diagnostic utility of the clinical exam, and the requirement of cerebrospinal fluid (CSF) testing for diagnosis, which traditionally has long turnaround times for culture results and can be affected by antibiotic therapy initiated before performing lumbar puncture.
Medical Doctors at Weill Cornell Medicine (New York, NY, USA) performed a retrospective pre-post intervention study that included adults ≥18 years of age who presented to the emergency department with suspected bacterial meningitis defined by the following criteria: (1) received empiric antibiotic therapy for bacterial meningitis; (2) had lumbar puncture performed in the emergency department; and (3) underwent microbiological testing with CSF culture in the preintervention period and multiplex PCR ME panel testing plus CSF culture in the postintervention period.
The team analyzed the use of the FilmArray meningitis/encephalitis (ME) panel (BioFire Diagnostics, LLC, Salt Lake City, UT, USA), which has been US Food and Drug Administration-approved for use in community-acquired CNS infections, has permitted rapid identification (within 1 hour) of 14 different viral, bacterial, and fungal agents associated with ME in CSF using a multiplex polymerase chain reaction (PCR) system. The scientists gathered data from annual chart reviews over a 3-year period before and after implementation of the ME multiplex PCR panel on February 14, 2017. There were 137 patients in the pre-panel period and 69 patients in the post-panel period.
The investigators reported that the positive detection rate of bacterial pathogens was 3/137 (2.2%) by CSF culture in the pre-multiplex PCR ME panel period and 3/69 (4.3%) by the multiplex PCR ME panel in the post-multiplex PCR ME panel period. There was no difference in the proportion of patients for whom any pathogen was detected by microbiological testing between pre- and post-multiplex PCR ME panel periods (17.5% versus 20.3%). They found that once the panel was implemented, 46% more patients had empiric antibiotic therapy discontinued or de-escalated compared with before the panel was used.
Among 14 patients in the post-multiplex PCR ME panel period for whom a pathogen was identified, three patients had therapy targeted to bacterial pathogens (two S. pneumoniae, one H. influenzae) and 11 to viral pathogens (five enterovirus, three herpes simplex virus 2, three varicella zoster virus). The average turnaround time for the multiplex PCR ME panel was 2.6 hours. In the pre-multiplex PCR ME panel period, the average turnaround time for viral pathogen testing (performed by a viral encephalitis PCR panel on CSF samples) was 71.3 hours.
The authors concluded that implementation of a multiplex PCR ME panel for testing of adult patients who present to the emergency department with suspected bacterial meningitis appears to reduce the duration of empiric antibiotic therapy, time to targeted therapy, and possibly hospital length of stay compared with traditional microbiological testing methods. The study was published in the October, 2021 issue of the journal Open Forum Infectious Diseases.
Related Links:
Weill Cornell Medicine
BioFire Diagnostics
Rapid diagnosis and treatment are critical to reducing morbidity and mortality; however, evaluation of suspected meningitis is complex and challenging due to its nonspecific presentation, the limited diagnostic utility of the clinical exam, and the requirement of cerebrospinal fluid (CSF) testing for diagnosis, which traditionally has long turnaround times for culture results and can be affected by antibiotic therapy initiated before performing lumbar puncture.
Medical Doctors at Weill Cornell Medicine (New York, NY, USA) performed a retrospective pre-post intervention study that included adults ≥18 years of age who presented to the emergency department with suspected bacterial meningitis defined by the following criteria: (1) received empiric antibiotic therapy for bacterial meningitis; (2) had lumbar puncture performed in the emergency department; and (3) underwent microbiological testing with CSF culture in the preintervention period and multiplex PCR ME panel testing plus CSF culture in the postintervention period.
The team analyzed the use of the FilmArray meningitis/encephalitis (ME) panel (BioFire Diagnostics, LLC, Salt Lake City, UT, USA), which has been US Food and Drug Administration-approved for use in community-acquired CNS infections, has permitted rapid identification (within 1 hour) of 14 different viral, bacterial, and fungal agents associated with ME in CSF using a multiplex polymerase chain reaction (PCR) system. The scientists gathered data from annual chart reviews over a 3-year period before and after implementation of the ME multiplex PCR panel on February 14, 2017. There were 137 patients in the pre-panel period and 69 patients in the post-panel period.
The investigators reported that the positive detection rate of bacterial pathogens was 3/137 (2.2%) by CSF culture in the pre-multiplex PCR ME panel period and 3/69 (4.3%) by the multiplex PCR ME panel in the post-multiplex PCR ME panel period. There was no difference in the proportion of patients for whom any pathogen was detected by microbiological testing between pre- and post-multiplex PCR ME panel periods (17.5% versus 20.3%). They found that once the panel was implemented, 46% more patients had empiric antibiotic therapy discontinued or de-escalated compared with before the panel was used.
Among 14 patients in the post-multiplex PCR ME panel period for whom a pathogen was identified, three patients had therapy targeted to bacterial pathogens (two S. pneumoniae, one H. influenzae) and 11 to viral pathogens (five enterovirus, three herpes simplex virus 2, three varicella zoster virus). The average turnaround time for the multiplex PCR ME panel was 2.6 hours. In the pre-multiplex PCR ME panel period, the average turnaround time for viral pathogen testing (performed by a viral encephalitis PCR panel on CSF samples) was 71.3 hours.
The authors concluded that implementation of a multiplex PCR ME panel for testing of adult patients who present to the emergency department with suspected bacterial meningitis appears to reduce the duration of empiric antibiotic therapy, time to targeted therapy, and possibly hospital length of stay compared with traditional microbiological testing methods. The study was published in the October, 2021 issue of the journal Open Forum Infectious Diseases.
Related Links:
Weill Cornell Medicine
BioFire Diagnostics
Latest Technology News
- Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
- Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
- Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
- Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
- Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
- Smartphones Could Diagnose Diseases Using Infrared Scans
- Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
- 3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
- POC Paper-Based Sensor Platform to Transform Cardiac Diagnostics
- Study Explores Impact of POC Testing on Future of Diagnostics
- Low-Cost, Fast Response Sensor Enables Early and Accurate Detection of Lung Cancer
- Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
- Lab-On-Chip Platform to Expedite Cancer Diagnoses
- Biosensing Platform Simultaneously Detects Vitamin C and SARS-CoV-2
- New Lens Method Analyzes Tears for Early Disease Detection
- FET-Based Sensors Pave Way for Portable Diagnostic Devices Capable of Detecting Multiple Diseases
Channels
Clinical Chemistry
view channelMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read moreMolecular Diagnostics
view channel
First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis
Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more
New Molecular Label to Help Develop Simpler and Faster Tuberculosis Tests
Tuberculosis (TB), the deadliest infectious disease globally, is responsible for infecting an estimated 10 million people each year and causing over 1 million deaths annually. While chest X-rays and molecular... Read more
Biomarker Discovery Paves Way for Blood Tests to Detect and Treat Osteoarthritis
The number of individuals affected by osteoarthritis is projected to exceed 1 billion by 2050. The primary risk factor for this common, often painful chronic joint condition is aging, and, like aging itself,... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more